Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS: FDA approves Ehave study on depression!!!
https://finance.yahoo.com/news/fda-grants-ehave-consent-proceed-130000072.html
FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
MIAMI, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, announced today that it received confirmation from the U.S. Food and Drug Administration ("FDA") that its review of Ehave's Investigational New Drug ("IND") application is complete. The FDA authorized Ehave to proceed with its clinical study, "An open label study of electrographic responses pre, during and post, a low dose, weekly intravenous ketamine infusion for 4 weeks, in a study population with major depression disorder (MDD)," submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ketamine HCl. The objective of this study is to characterize the change in EEG response of patients with MDD, during and 4 weeks after a course of IV ketamine infusions.
The clinical study includes 35 participants with Major Depression Disorder. It will include subjects with an inadequate response to at least two FDA-approved antidepressant therapies, including the current course of antidepressant therapy, at a sufficient dose and duration for the current episode. An electroencephalography machine measures the brain’s activity at baseline and after four weekly low-dose IV ketamine study treatments. The purpose of the study is to learn about the neurological responses seen on EEGs of participants receiving low-dose IV ketamine therapy. Dr. Jeffrey Kamlet and Tristar Wellness will complete the study. Dr. Kamlet has served as the principal investigator on more than 20 major pharmaceutical trials.
More than 264 million people across the globe suffer from depression. As a pervasive and often chronic health condition, depression is a global health burden and a significant source of disability. While depression might be considered a non-fatal health burden, severe depressive symptoms can lead to suicide, which is the second most common cause of death in people aged 15-29 years. Common treatments for depression include pharmacological interventions such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and tricyclic antidepressants (TCAs) and psychotherapy; however, the efficacy of these interventions often fails in severe cases.
Ketamine is a dissociative anesthetic, used most frequently in veterinary medicine and pediatrics, that has been repurposed as an off-label analgesic and antidepressant. Extensive investigation of its rapid antidepressive effects have been a breakthrough offering a potential reprieve to those suffering from MDD. Ketamine has also been shown to reduce suicidal ideation in depressed patients at risk for suicide. Similarly, the administration of ketamine was effective at reducing depressive symptoms, acute suicidal behavior, and mood lability in the youth with treatment-resistant depression (TRD) and bipolar disease. Intranasal esketamine is the only form of ketamine that has been FDA-approved as a treatment for TRD. However, clinical research and real-world feasibility have established significant drawbacks to intranasal ketamine, including patient discomfort with administration, greater risk of diversion to the illicit market, and potentially serious adverse reactions. Intravenous use of racemic ketamine is the more established route of administration as it has long been used as an anesthetic at much higher doses. Ehave management believes intravenous administration of ketamine includes benefits which include greater dose control and reduced cost of drug acquisition. This belief is the fundamental premise that has led to many dedicated outpatient clinics offering intravenous ketamine therapy for MDD across the United States.
"The upcoming clinical study for intravenous ketamine infusion in patients with treatment refractory major depressive disorder represents a significant milestone for Ehave's clinical programs," commented Ben Kaplan, CEO of Ehave. "There are many common pharmacological treatments for major depression disorder; however, the efficacy of these drugs often fails in severe cases. Intravenously administered ketamine may offer the potential for the remission of the symptoms in patients with MDD; however, it has not yet been approved by FDA for this purpose. This study will use an electroencephalography machine to measure the brain's activity and response while the intravenous ketamine is being delivered."
Dr. Ali from the Medical Advisory board says, “Studying the effects of IV ketamine by observing changes in brain activity on EEG is an important step in furthering Ehave’s mission. This approach can help advance the identification of potential biomarkers, which could one day be used to identify the specific patients who will respond best to ketamine intervention upfront, allowing the recommendation to made sooner in the course of illness and decreasing the amount of trial and error with treatment options.”
About Ehave, Inc.
Ehave is a leading healthcare services and technology company focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address many mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave’s operations span the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.
Volume picking up again
Starting to trade above 1mill shares per day, and even closer to 2mill
News this weekend
Healthcare data huge market
...and sounds bit like they will be exploring data security for healthcare sector, which needed from all ransomware attacks
S-4 merger should go effective soon
Once this becomes effective this stock will gap up to $1.00 wicked fast.
Wouldn't be surprised it happens this month
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001931373&owner=include&count=40
$MLRT Extinguishes Toxic Debt
MetAlert Extinguishes Toxic Debt And Launches New Medical Devices
Research Now Price Targets MLRT at $1 - Making it a Stock to Watch
https://marketsherald.com/metalert-launches-new-medical-devices/
Just 4053 shares left @ .45
Remove All or None from limit orders, and set to GTC and market makers will show your order as best bid
$MLRT eliminates toxic notes (no dilution)
MetAlert (MLRT) Eliminates Toxic Debt, Launches New Medical Device Products
https://ludlowresearch.com/mlrt-eliminates-toxic-debt-launches-new-medical-device/
$MLRT eliminates toxic notes (no dilution)
MetAlert (MLRT) Eliminates Toxic Debt, Launches New Medical Device Products
https://ludlowresearch.com/mlrt-eliminates-toxic-debt-launches-new-medical-device/
Volume picking up!
This could be primed for run back above .01+
Launching product roadmap
EHVVF interview coming!
$MLRT - eliminates toxic debt (low float)
$MLRT - eliminates toxic debt (low float)
+48% to .007
Stock at key breakout point
This could suddenly make run for .01+ here
NEWS OUT!
https://finance.yahoo.com/news/ehave-shareholder-ceo-ben-kaplan-130000012.html
MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan.
Dear Fellow Shareholders
As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in several decades, and higher interest rates. Despite these challenges and many others, I am very proud of our Ehave team's accomplishments in advancing our business plan. Our team executed several vital acquisitions, expanded our research capabilities, and realized many more achievements in our effort to continue to build on our strong foundation.
At the outset, I would like to provide an update on the triangular merger between our publicly traded Mycotopia Therapies (OTC: TPIA) subsidiary, Ei.Ventures, and PSLY.com. The $380 million transaction is structured to close when PSLY.com receives approval for trading on NASDAQ. We are following the procedures for this process as set forth by NASDAQ and the SEC. All parties involved are committed to completing the transaction. This transaction is important to Ehave shareholders because Ehave owns approximately 9,793,754 shares of Mycotopia Therapies. I expect to provide additional updates on this transaction and how it will affect our Ehave shareholders in the near future.
KetaDASH
I want to highlight several significant milestones our Ehave team has achieved in 2022. In February, Ehave purchased 100% of Rejuv IV, a mobile IV therapy provider in the San Francisco Bay Area. Rejuv IV became KetaDASH, a wholly owned subsidiary of Ehave, Inc. KetaDASH provides mobile Ketamine treatments for treatment-resistant depression, anxiety, PTSD, and other conditions, as well as IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. After an initial telemedicine visit, a team of experienced physicians, therapists, and nurses administer every KetaDASH treatment in the patient's home, office, or mobile location. This innovative service departs from in-clinic intravenous, treatment, or unsupervised telehealth models to an at-home ketamine administration with telehealth and in-person medical supervision.
A typical KetaDASH experience incorporates a prescribing doctor, a nurse for administration and monitoring, and psychotherapists for integration, all from the comfort of the patient's home. Our KetaDASH team is pioneering efforts in precision medicine through Ehave’s partnership with Entheon Biomedical Corp.’s (CSE: ENBI) (OTCQB: ENTBF) HaluGen Life Sciences division. Our KetaDASH subsidiary is one of the first psychedelic companies to test patients with HaluGen’s expanded psychedelics genetic testing panel. This panel analyzes a series of relevant DNA biomarkers and utilizes pre-screening mental health surveys in order to provide insights into an individual's risk and potential for adverse reactions with the use of ketamine. Ehave's KetaDASH subsidiary is fully operational in Sacramento and San Francisco.
KetaDASH Miami
In June, Ehave took delivery of its first mobile KetaDASH unit, a custom high-end medical van utilizing KetaDASH's software platform. The KetaDASH Mobile Unit was specifically designed to focus on the efficacy of the treatment in a relaxed setting with the patient’s safety and comfort in mind. At the present time, KetaDASH is focusing on health, wellness, and mental health in the Miami area. KetaDASH currently does not offer ketamine treatments in Miami, but plans to start offering them in the first half of 2023.
KetaDASH Miami currently offers IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. These infusions include IV Drip Detox and Hangover Cures, IV Vitamin Therapy for Pain Management, IV Hydration Therapy for Health & Wellness, and IV Therapy for Athletic Advantage and Fitness Recovery. Every infusion is administered by a qualified health care professional to ensure the safety of our patients.
Follow KetaDASH on Instagram at www.instagram.com/ketadash.usa.
MetaHealthU
MetaHealthU provides patients with a way to integrate providers, create troves of usable data for researchers, and clinicians to improve the care our nation's health system provides to its patients, providing a platform for precision health and giving patients ownership of their data. MetaHealthU focuses on interoperability, population health, and data ownership, and it has created a system that will work by providing patients the opportunity to own their health data.
We reached a milestone of 600 new users on our MetaHealthU platform during the last half of the year. The new users have found tremendous success with the platform and have compiled usable data on specific medical conditions like erectile dysfunction and fatigue. Many of these users have also used our mobile services in KetaDASH Miami.
Our Ehave team developed MetaHealthU as a powerful mobile application platform that empowers individuals to take complete control of their health and their healthcare data. With MetaHealthU, users can securely track all their health data from wearables, Electronic Health Records Systems (EHRs), doctors, and medical labs. The app is available for iOS 11.0 or later and Android. It includes a "digital file cabinet" for medical records. Users can log into their patient portals on various healthcare systems and medical labs and download their medical records in the digital file cabinet. Its features include easy-to-use navigation and search capabilities for users to collect, file, and tag their medical records on a mobile device. More information on MetaHealthU, as well as a free download of the app, can be found at https://apps.apple.com/us/app/metahealthu/id1600512401.
MetaHealthYuru
MetaHealthYuru is a personal mental health monitor that screens for early signs of mental health conditions, such as stress and depression. MetaHealthYuru uses voice analysis to screen for early signs of mental health conditions using a speech-based AI technology. Our MetaHealthYuru platform could potentially predict risk for various types of depression and mood and anxiety-based disorders years before a clinical diagnosis is obtained. This is accomplished by using vocal biomarkers to recognize your real emotional state and mood while tracking your mental health. Our technology can help detect and monitor subtle changes in the mental state by assessing individuals more frequently and objectively than the assessments used today. MetaHealthYuru can track your emotions and mood, analyze your mental state, and suggest potential treatments available for improving your mental well-being.
2023 and Beyond
In 2022 our Ehave team focused its efforts on developing our existing projects. We started the year with a large number and developed suitable metrics to gauge which ones will benefit the most from our resources. Moving forward, we intend to unlock the value created with our Mycotopia Therapies subsidiary and some of the company’s other investments. We also intend to focus our efforts on expanding our KetaDASH and MetaHealthU subsidiaries to propel Ehave into 2023 and beyond.
Stock wildly undervalued here
S-4 take around 5-6 months to get approved
It isn't like posting on a message board. When you submit an S filing with SEC it can take roughly 5-6 months to get approved, in general.
They filed original S-4 in August so really should be getting close in Dec or Jan
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001931373&owner=include&count=40
....and no, there's isn't anyone you can pay or call to speed it up. It's the Federal regulators you just have to go through their process.
It should be getting close to becoming effective soon though.
$ELEK .07 patent on EV Multi-Port charger
This could become standard in all EV's going forward
https://www.cnbc.com/quotes/ELEK
$ELEK .07 patent on EV Multi-Port charger
This could become standard in all EV's going forward
https://www.cnbc.com/quotes/ELEK
EHVVF (005) mental health & wellness
As economy and stocks drop you will see anxiety and depression increase.
EHVVF develops treatments and applications for mental health wellness
https://www.otcmarkets.com/stock/ehvvf/security
Recession means more business for EHVVF
EHVVF (005) mental health & wellness
As economy and stocks drop you will see anxiety and depression increase.
EHVVF develops treatments and applications for mental health wellness
https://www.otcmarkets.com/stock/ehvvf/security
Just 4138 shares left @ .45
MLRT retains banker to up list stock
LOS ANGELES, CALIFORNIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- MetAlert, Inc. (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, announced today that it has engaged Joseph Gunnar & Co., LLC as its financial advisor. As the Company articulates its growth strategy to the investment community, Joseph Gunnar will advise on potential financing alternatives and acquisitions as well as plans to up-list to a national exchange.
https://finance.yahoo.com/news/metalert-engages-joseph-gunnar-co-131400561.html
It should never have been that high
That was utterly insane it went to $8 and was result of super liquidity event in market when Fed rates were 0% and maximum liquidity was being pumped into market. Even more so than from Dotcom era.
We will never see that again in our lives.
But .15 to .40 range for ELEK is not out of question once broader markets recover some. That would be more realistic, and maybe higher if can score some real partnerships and revenues.
Fed to slowdown pace of hikes
Signals we are approaching end of rate hike cycle, and market surging on shorts covering. This should spill down to microcaps as well
EV stocks surging on Fed news
Fed saying will start slowing pace of hikes, and take wait and see into news year. This signals the brutal hikes are winding down....look for shorts to cover across the market